Mr. Speaker, in connection with the current review, all the members agree that developing countries must have access to cheaper versions of patented drugs to fight AIDS, malaria and tuberculosis. However, standard procedures must be followed, with indepth consideration of this proposal by the Standing Committee on Industry, Science and Technology.
Given the Minister of Industry's history with generic drug companies, what type of legislative agenda will he propose to the House? Will he use this opportunity to help his friends at generic drug companies or will he implement real measures to help the poor and the sick?